Pune: Emcure Pharmaceuticals Ltd. announced the launch of Arth, a new product line designed to support women through their menopausal journey.
Arth offers a comprehensive approach to the physical, emotional, and mental well-being of women during menopause, combining scientific research with an understanding of their specific health needs.
Menopause is a natural phase in a woman’s life, often accompanied by a range of physical and psychological symptoms. Perimenopause can last up to 10 years and may present more than 30 different symptoms, significantly impacting daily life. According to a study conducted by Emcure, 96% of women experience
Menopausal symptoms that disrupt their day-to-day activities, yet many avoid seeking treatment due to a lack of awareness and social stigma. Arth aims to empower women to navigate this phase with better health and confidence, offering a holistic solution without the judgment often associated with menopause.
The Arth range includes various products tailored to alleviate common menopausal symptoms. These include multi-symptom capsules featuring chasteberry, capsules for tender breast relief, tablets for bone health, and Brahmi capsules for brain fog.
This carefully curated range addresses multiple aspects of the menopausal journey, making it easier for women to maintain their health and well-being.
Instead of traditional awareness campaigns, Emcure is partnering with popular stand-up comedians to bring attention to menopause in a light-hearted manner, breaking the stigma and encouraging open discussions.
Namita Thapar, Whole-time Director of Emcure Pharmaceuticals Ltd., said, “With Arth, our goal is to raise awareness and improve access to affordable products that support women’s health and self-empowerment during menopause.”
The Arth product line is meticulously developed to address common menopause symptoms such as hot flashes, night sweats, mood swings, and vaginal dryness, providing women with thoughtful yet practical solutions to manage this critical stage of their natural cycle.